Hypothesis Emodin reprograms senescent cells by inhibiting EGFR and CDK2, shifting their secretory phenotype from a pro‑inflammatory SASP to a regenerative secretome without inducing cell death.

Mechanistic Rationale

• EGFR drives MAPK/NF‑κB signaling that amplifies IL‑6, IL‑8 and TNF‑α secretion in senescent cells Emodin suppresses NF‑κB via EGFR/MAPK.
• CDK2 activity sustains transcriptional programs that maintain SASP components; its inhibition reduces NF‑κB nuclear translocation Emodin inhibits CDK2/cyclin A.
• Dual EGFR/CDK2 blockade therefore attenuates pathological SASP while preserving factors such as VEGF and HGF that depend on alternative pathways (e.g., HIF‑1α, SMAD) Emodin sensitizes EGFR inhibition via Stat3.
• In macrophages and CKD models, emodin lowers EGFR and Ras expression, dampening pro‑inflammatory output Emodin attenuates EGFR/Ras in macrophages.

Testable Predictions

1. Treatment of induced senescent fibroblasts with low‑micromolar emodin will decrease IL‑6, IL‑8, TNF‑α levels by >50 % while increasing VEGF and HGF secretion by ≥20 % relative to untreated senescent controls.
2. The shift will be absent in cells where EGFR is knocked‑out or CDK2 is constitutively active, confirming target dependence.
3. Conditioned medium from emodin‑treated senescent cells will promote migration and tube formation of endothelial cells in vitro, whereas medium from untreated senescent cells will inhibit these functions.
4. In a murine model of acute lung injury, local emodin delivery will reduce neutrophil infiltration (inflammatory read‑out) and improve alveolar repair (regenerative read‑out) without reducing p16^INK4a^‑positive senescent cell numbers.

Experimental Approach

• Induce senescence in human diploid fibroblasts using irradiation (10 Gy) or oncogenic RAS; verify by SA‑β‑gal and p16^INK4a^.
• Treat with emodin (0.5‑5 µM) for 48 h; collect supernatant for cytokine arrays (IL‑6, IL‑8, TNF‑α, VEGF, HGF).
• Use siRNA or CRISPR to knockdown EGFR or overexpress CDK2‑T160D to test necessity.
• Apply conditioned media to HUVEC migration (scratch assay) and tube formation (Matrigel) assays.
• In vivo: intratracheal emodin (2 mg/kg) in LPS‑induced lung injury mice; measure BALF neutrophils, collagen deposition, and p16^INK4a^ immunostaining at day 3 and day 7.

Potential Implications If emodin can reprogram rather than eliminate senescent cells, it offers a senomorphic strategy that preserves the damage‑signaling and immune‑recruitment roles of senescence while tipping the balance toward tissue repair. This approach may avoid the proliferative burst associated with senolytic clearance and could be beneficial in settings where transient senescence is advantageous, such as wound healing or post‑injury regeneration.